SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)

• E. Nadal ^[1] ; J. Bosch-Barrera ^[1] ; S. Cedrés ^[8] ; J. Coves ^[2] ; R. García-Campelo ^[3] ; M. Guirado ^[4] ; R. López-Castro ^[5] ; A. L. Ortega ^[6] ; D. Vicente ^[9] ; J. de Castro-Carpeño ^[7]
  1. [1] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  2. [2] Hospital Son Llàtzer

     Hospital Son Llàtzer

     Palma de Mallorca, España

     
  3. [3] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  4. [4] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  5. [5] Hospital Universitario de Valladolid

     Hospital Universitario de Valladolid

     Valladolid, España

     
  6. [6] Hospital Universitario de Jaén

     Hospital Universitario de Jaén

     Jaén, España

     
  7. [7] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  8. [8] Vall d’Hebron Instituto de Oncología
  9. [9] Hospital Universitario Virgen de Macarena

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 5 (May), 2021 (Ejemplar dedicado a: SEOM clinical guidelines 2020), págs. 980-987
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 1 Cita
• Resumen

  • Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future.